Merck's monoclonal antibody Enflonsia gains FDA approval for preventing RSV in infants, entering a competitive market alongside Sanofi and AstraZeneca's product. This regulatory milestone coincides with the abrupt disbandment of the CDC's ACIP vaccine panel by HHS Secretary Robert F. Kennedy Jr., creating uncertainty around upcoming vaccine recommendations and potentially impacting pediatric immunization strategies.